FDA Grants Fast Track Designation for Seribantumab in NSCLC

Oncology Times

CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions.

Carrizosa · American Society of Clinical Oncology (ASCO)

A Phase 1 Study Combining the HER3 Antibody Seribantumab (MM-121) and Cetuximab with and Without Irinotecan

Cleary · Investigational New Drugs

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer

Sequist · The Oncologist

Systems Biology Driving Drug Development: from Design to the Clinical Testing of the anti-ErbB3 Antibody Seribantumab (MM-121)

Schoeberl · npj Systems Biology and Applications

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab

Orlova · Molecular Pharmaceutics

Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer

Liu · American Society of Clinical Oncology

Phase 1 Dose Escalation Study of Seribantumab (MM-121), an anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Denlinger · Investigational New Drugs

P2.13-45 SHERLOC: A Phase 2 Study of Seribantumab in Combination with Docetaxel in Patients with Heregulin Positive, Advanced NSCLC

Sequist · Journal of Thoracic Oncology

Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody Seribantumab

Seribantumab, an anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-positive Breast Cancer Model

Curley · American Association for Cancer Research

The anti-HER3 Monoclonal Antibody Seribantumab Effectively Inhibits Growth of Patient-derived and Isogenic Cell Line and Xenograft Models with NRG1 Rearrangements

Odintsov · European Journal of Cancer